PL3503890T3 - Stosowanie pridopidyny w leczeniu dystonii - Google Patents
Stosowanie pridopidyny w leczeniu dystoniiInfo
- Publication number
- PL3503890T3 PL3503890T3 PL17844432.9T PL17844432T PL3503890T3 PL 3503890 T3 PL3503890 T3 PL 3503890T3 PL 17844432 T PL17844432 T PL 17844432T PL 3503890 T3 PL3503890 T3 PL 3503890T3
- Authority
- PL
- Poland
- Prior art keywords
- pridopidine
- dystonia
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662379175P | 2016-08-24 | 2016-08-24 | |
| US201662395319P | 2016-09-15 | 2016-09-15 | |
| PCT/US2017/048458 WO2018039475A1 (en) | 2016-08-24 | 2017-08-24 | Use of pridopidine for treating dystonias |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3503890T3 true PL3503890T3 (pl) | 2025-03-24 |
Family
ID=61246309
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17844432.9T PL3503890T3 (pl) | 2016-08-24 | 2017-08-24 | Stosowanie pridopidyny w leczeniu dystonii |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11826361B2 (pl) |
| EP (1) | EP3503890B1 (pl) |
| JP (2) | JP7278210B2 (pl) |
| CN (1) | CN110012661A (pl) |
| AU (1) | AU2017315781B2 (pl) |
| BR (1) | BR112019003731A2 (pl) |
| CA (1) | CA3035099C (pl) |
| DK (1) | DK3503890T3 (pl) |
| ES (1) | ES3009437T3 (pl) |
| MX (1) | MX2019002190A (pl) |
| PL (1) | PL3503890T3 (pl) |
| WO (1) | WO2018039475A1 (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| US11090297B2 (en) | 2013-06-21 | 2021-08-17 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating huntington's disease |
| WO2014205229A1 (en) | 2013-06-21 | 2014-12-24 | IVAX International GmbH | Use of high dose pridopidine for treating huntington's disease |
| JP6887952B2 (ja) | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
| US11471449B2 (en) | 2015-02-25 | 2022-10-18 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine to improve cognitive function and for treating Alzheimer's disease |
| AU2017315781B2 (en) | 2016-08-24 | 2021-01-28 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating dystonias |
| AU2017315783C1 (en) | 2016-08-24 | 2020-12-24 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating a subject with early stage huntington disease |
| US12102627B2 (en) | 2016-09-16 | 2024-10-01 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for treating rett syndrome |
| US12036213B2 (en) | 2017-09-08 | 2024-07-16 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating drug induced dyskinesias |
| MX2020002645A (es) | 2017-09-08 | 2021-06-10 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento de las discinesias inducidas por fármacos. |
| CN115551505A (zh) | 2020-05-04 | 2022-12-30 | 普瑞尼亚神经治疗有限公司 | 使用选择性s1r激动剂治疗病毒性感染、疾病或病症 |
| WO2024142058A1 (en) * | 2022-12-27 | 2024-07-04 | Prilenia Neurotherapeutics Ltd. | Pridopidine for treating juvenile huntington's disease |
| WO2024258929A1 (en) * | 2023-06-12 | 2024-12-19 | Unravel Biosciences, Inc. | Methods for treating diseases associated with taf1 loss of function |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9904724D0 (sv) | 1999-12-22 | 1999-12-22 | Carlsson A Research Ab | New modulators of dopamine neurotransmission I |
| SE0401465D0 (sv) * | 2004-06-08 | 2004-06-08 | Carlsson A Research Ab | New substituted piperdines as modulators of dopamine neurotransmission |
| NZ552411A (en) * | 2004-06-08 | 2010-04-30 | Nsab Af Neurosearch Sweden Ab | New disubstituted phenylpiperidines/piperazines as modulators of dopamine neurotransmission |
| KR101319235B1 (ko) | 2004-10-13 | 2013-10-16 | 아이백스 인터내셔널 게엠베하 | 4-(3-메탄설폰일페닐)-1-ｎ-프로필-피페리딘의 합성 공정 |
| SE529246C2 (sv) * | 2005-10-13 | 2007-06-12 | Neurosearch Sweden Ab | Nya disubstituerade fenyl-piperidiner som modulatorer för dopaminneurotransmission |
| BRPI0810161A2 (pt) | 2007-04-12 | 2014-12-30 | Nsab Af Neurosearch Sweden Ab | Composto, preparação farmacêutica, composição farmacêutica, e, uso de um composto |
| US8562488B2 (en) * | 2009-10-05 | 2013-10-22 | The Cleveland Clinic Foundation | Systems and methods for improving motor function with assisted exercise |
| WO2011107583A1 (en) * | 2010-03-04 | 2011-09-09 | Nsab, Filial Af Neurosearch Sweden Ab, Sverige | Substituted 4-phenyl-n-alkyl-piperidines for preventing onset or slowing progression of neurodegenerative disorders |
| EP2611759A1 (en) | 2010-09-03 | 2013-07-10 | Ivax International Gmbh | Deuterated analogs of pridopidine useful as dopaminergic stabilizers |
| JP6189299B2 (ja) | 2011-09-07 | 2017-08-30 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | プリドピジン塩酸塩の新規な多形形態 |
| EP2787997A4 (en) * | 2011-12-08 | 2015-05-27 | Ivax Int Gmbh | HYDROBROMIDE SALT OF PRIDOPIDINE |
| US9744155B2 (en) | 2012-03-28 | 2017-08-29 | Ixcela, Inc. | IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk |
| JP6177875B2 (ja) | 2012-04-04 | 2017-08-09 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハーＴｅｖａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｔｅｒｎａｔｉｏｎａｌ ＧｍｂＨ | 併用療法のための医薬組成物 |
| US20140037850A1 (en) * | 2012-08-06 | 2014-02-06 | General Electric Company | Corrosion and wear resistant organic coatings |
| WO2014205229A1 (en) | 2013-06-21 | 2014-12-24 | IVAX International GmbH | Use of high dose pridopidine for treating huntington's disease |
| KR102479759B1 (ko) | 2014-01-22 | 2022-12-21 | 프리레니아 뉴로테라퓨틱스 엘티디. | 프리도피딘의 변형된 방출 제제 |
| TW201613859A (en) | 2014-06-30 | 2016-04-16 | Teva Pharma | Analogs of PRIDOPIDINE, their preparation and use |
| JP2018505147A (ja) | 2014-12-22 | 2018-02-22 | テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー | プリドピジンのｌ−酒石酸塩 |
| JP6887952B2 (ja) | 2015-02-25 | 2021-06-16 | プリレニア ニューロセラピューティクス リミテッド | 認知機能を改善するため、およびアルツハイマー病を治療するためのプリドピジンの使用 |
| WO2016138135A1 (en) | 2015-02-25 | 2016-09-01 | Teva Pharmaceuticals International Gmbh | Sigma-1 receptor modulators for treating huntington's disease |
| US20170020854A1 (en) | 2015-07-22 | 2017-01-26 | Teva Pharmaceuticals International Gmbh | Pridopidine base formulations and their use |
| AR105434A1 (es) | 2015-07-22 | 2017-10-04 | Teva Pharmaceuticals Int Gmbh | Proceso para preparar pridopidina |
| WO2017147366A1 (en) | 2016-02-24 | 2017-08-31 | Teva Pharmaceuticals International Gmbh | Treatment of neurodegenerative eye disease using pridopidine |
| AU2017315783C1 (en) * | 2016-08-24 | 2020-12-24 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating a subject with early stage huntington disease |
| AU2017315781B2 (en) | 2016-08-24 | 2021-01-28 | Prilenia Neurotherapeutics Ltd | Use of pridopidine for treating dystonias |
| EP3512517B1 (en) | 2016-09-15 | 2025-03-19 | Prilenia Neurotherapeutics Ltd. | Use of pridopidine for the treatment of anxiety and depression |
| DK3512506T3 (da) | 2016-09-16 | 2022-04-19 | Prilenia Neurotherapeutics Ltd | Anvendelse af pridopidin til behandling af retts syndrom |
| WO2018053275A1 (en) | 2016-09-16 | 2018-03-22 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of familial dysautonomia |
| WO2018136600A1 (en) | 2017-01-20 | 2018-07-26 | Teva Pharmaceuticals International Gmbh | Use of pridopidine for the treatment of fragile x syndrome |
| DK3668509T3 (da) | 2017-08-14 | 2023-02-20 | Prilenia Neurotherapeutics Ltd | Fremgangsmåde til behandling af amyotrofisk lateralsklerose med pridopidin |
| MX2020002645A (es) | 2017-09-08 | 2021-06-10 | Prilenia Neurotherapeutics Ltd | Pridopidina para el tratamiento de las discinesias inducidas por fármacos. |
-
2017
- 2017-08-24 AU AU2017315781A patent/AU2017315781B2/en active Active
- 2017-08-24 MX MX2019002190A patent/MX2019002190A/es unknown
- 2017-08-24 EP EP17844432.9A patent/EP3503890B1/en active Active
- 2017-08-24 PL PL17844432.9T patent/PL3503890T3/pl unknown
- 2017-08-24 DK DK17844432.9T patent/DK3503890T3/da active
- 2017-08-24 ES ES17844432T patent/ES3009437T3/es active Active
- 2017-08-24 CA CA3035099A patent/CA3035099C/en active Active
- 2017-08-24 BR BR112019003731A patent/BR112019003731A2/pt not_active IP Right Cessation
- 2017-08-24 CN CN201780066796.2A patent/CN110012661A/zh active Pending
- 2017-08-24 JP JP2019531546A patent/JP7278210B2/ja active Active
- 2017-08-24 WO PCT/US2017/048458 patent/WO2018039475A1/en unknown
-
2019
- 2019-02-24 US US16/283,784 patent/US11826361B2/en active Active
-
2021
- 2021-05-06 JP JP2021078788A patent/JP7278327B2/ja active Active
-
2023
- 2023-10-19 US US18/489,846 patent/US20240075021A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN110012661A (zh) | 2019-07-12 |
| AU2017315781A1 (en) | 2019-04-11 |
| US20190192496A1 (en) | 2019-06-27 |
| CA3035099C (en) | 2023-01-17 |
| ES3009437T3 (en) | 2025-03-26 |
| US11826361B2 (en) | 2023-11-28 |
| US20240075021A1 (en) | 2024-03-07 |
| WO2018039475A1 (en) | 2018-03-01 |
| CA3035099A1 (en) | 2018-03-01 |
| AU2017315781B2 (en) | 2021-01-28 |
| BR112019003731A2 (pt) | 2019-07-16 |
| JP2019524897A (ja) | 2019-09-05 |
| EP3503890A4 (en) | 2020-05-06 |
| DK3503890T3 (da) | 2025-01-27 |
| EP3503890B1 (en) | 2024-12-18 |
| WO2018039475A8 (en) | 2018-10-04 |
| MX2019002190A (es) | 2019-09-11 |
| JP2021119189A (ja) | 2021-08-12 |
| JP7278210B2 (ja) | 2023-05-19 |
| JP7278327B2 (ja) | 2023-05-19 |
| EP3503890A1 (en) | 2019-07-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL281793A (en) | Use of cannabinoids in the treatment of epilepsy | |
| HK1256380A1 (zh) | 修飾的細胞和治療方法 | |
| PL3503890T3 (pl) | Stosowanie pridopidyny w leczeniu dystonii | |
| HK1250376A1 (zh) | 用於癌症的治療和診斷方法 | |
| HUE054548T2 (hu) | Amino-triazolopiridin vegyületek és azok alkalmazása rák kezelésében | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| MA45192A (fr) | Traitement d'association | |
| RS62164B1 (sr) | Sulfoniluree i srodna jedinjenja i njihova upotreba | |
| DK3142637T3 (da) | Keratin treatment formulations and methods | |
| HUE061761T2 (hu) | Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében | |
| BR112018000129A2 (pt) | oxiesteróis e seus métodos de utilização | |
| EP3601536A4 (en) | TREATMENT PROCESSES | |
| DK3778595T3 (da) | Pancreatitisbehandling | |
| EP3564335A4 (en) | SURFACE TREATMENT AGENT | |
| DK3474802T3 (da) | Medicinsk forbinding | |
| IL258259A (en) | Adjunctive therapy with 25-hydroxyvitamin d and articles therefor | |
| EP3479817A4 (en) | COSMETIC PRODUCT. | |
| DK3231444T3 (da) | Ny behandling | |
| IL262926A (en) | Mic-1 compounds and use thereof | |
| EP3448263A4 (en) | Electrotherapeutic treatment | |
| EP3481952A4 (en) | METHYLATION MARKERS IN THE TREATMENT OF LEUKEMIA AND USES THEREOF | |
| DK3408265T3 (da) | Terapeutiske forbindelser | |
| HK1257539A1 (zh) | 新的化合物及其用途 | |
| HUE058314T2 (hu) | Pridopidin alkalmazása Rett-szindróma kezelésére | |
| EP3512553A4 (en) | KLRG1 EXHAUST THERAPY |